Single-stage Surgery With Antibiotic-loaded Hydrogel Coated Implants Versus Two Stage Surgery for Secondary Prevention of Complex Chronic Periprosthetic Hip Joint Infection (SINBIOSE-H)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04251377|
Recruitment Status : Recruiting
First Posted : January 31, 2020
Last Update Posted : December 14, 2022
Each year, around 1500 infected Total Hip Arthroplasties (THA) need non-conservative surgery, remaining an issue for patients and healthcare units. The recommended treatment, relying on cohort reviews and international consensus follows a two-stage protocol. This protocol implies a first surgery to remove all infected implants and at least 6 weeks of antibiotic treatment without implant, then usually an antibiotic-free period and only then a second surgery to put back new implants and start the rehabilitation protocol, with usually more than a week of a second hospital stay. Between both surgeries, full-weight bearing is prohibited and joint stiffness and/or pain are rather usual complications. Failure rate is estimated at 10% in this two-stage strategy. The single-stage procedure (i.e. implanting back a new prosthesis during the same surgery after implant removal, synovectomy and lavage) is thought to be less susceptible to late functional complications (i.e. pain, stiffness and muscle deficiency) with a shorter, single hospital stay.
Although, with single-stage surgery, infection control could be less efficient because most pathogens produce during the first hours of infection an antibiotic-resistant layer called biofilm, allowing them to colonize and adhere to foreign objects like implants. This single-surgery protocol thus highly relies on antibiotics and has a list of contra-indications (based on experts' consensus): the presence of damaged soft tissues or a sinus tract, unknown pathogens, difficult to treat micro-organisms, severe immunosuppression and for many surgeons, each time a bone graft is necessary. Most of these contra-indications are directly related to the biofilm.
As no randomized control trial has ever compared single-stage versus two-stage surgery, the level of evidence for recommending one procedure over the other is low.
We conducted a survey that showed that most of the French reference centers have already switched to single stage surgery for single-stage non contra-indicated cases.
An antibiotic-loaded hydrogel coating (Defensive Antiadhesive Coating®, Novagenit SRL), has been proven to mechanically prevent the biofilm formation, while allowing a prolonged intraarticular antibiotic release, in a randomized controlled trial in primary prevention of infection in THA.
The addition of this biofilm inhibitor to a single-stage surgery might stand as a promising strategy for secondary prevention of peri-prosthetic hip joint infection. Moreover, using this device to prevent biofilm formation could expand one stage surgery to patients that are "normally" contra-indicated to one stage surgery.
|Condition or disease||Intervention/treatment||Phase|
|Hip Prosthesis Infection||Device: Defensive Antiadhesive Coating DAC®, Novagenit SRL||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||440 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Single-stage Surgery With Antibiotic-loaded Hydrogel Coated Implants Versus Two Stage Surgery for Secondary Prevention of Complex Chronic Periprosthetic Hip Joint Infection SINBIOSE-H.|
|Actual Study Start Date :||September 30, 2021|
|Estimated Primary Completion Date :||December 2024|
|Estimated Study Completion Date :||December 2026|
Experimental: Single-stage surgery + DAC® + topical antibiotics
Experimental group is composed of single-stage procedure associated to the use of biofilm inhibitor (Defensive Antibacterial Coating® DAC®) and topical antibiotics=new strategy
Device: Defensive Antiadhesive Coating DAC®, Novagenit SRL
DAC gel, mixed with topical antibiotics is applied on the surface of the implants before implantation, in a sterile environment in the operating room.
The topical antibiotics will be added to the reconstituted DAC® gel preparation, at the discretion of the physician, on the basis of pre-operative culture.
No Intervention: control group : two-stage surgery
Control group is composed of two-stage procedure without biofilm inhibitor (standard protocol)
- Recurrence of clinically diagnosed infection relapse of the periprosthetic joint [ Time Frame: Years : 2 ]
The periprosthetic joint infection is defined according to the Musculoskeletal Infection Society criteria:
- Two positive periprosthetic cultures with phenotypically identical organisms
- or a sinus tract communicating with the joint,
or having 3 of 5 minor criteria:
- Elevated serum C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR);
- Elevated synovial fluid white blood cell (WBC) count;
- Elevated synovial fluid polymorphonuclear neutrophil percentage (PMN%);
- Positive histological analysis of periprosthetic tissue;
- A single positive culture.
- Harris Hip Score (HHS) results [ Time Frame: Years : 2 ]Harris Hip Score (HHS) contains 10 items with maximum score at 100 for a perfect hip and minimum score at 0 for a very bad result.
- Postel-Merle d'Aubigné (PMA) results [ Time Frame: Years : 2 ]Postel-Merle d'Aubigné (PMA) contains 3 items (pain, mobility and functional hip) with maximum score at 18 for a perfect hip and minimum score at 0 for a very bad result.
- Hip dysfunction and Osteoarthritis Outcome Score (HOOS) results [ Time Frame: Years : 2 ]Hip dysfunction and Osteoarthritis Outcome Score contains 6 items (symptoms, stiffness, pain, function and daily life, sport and leisure activities, quality of life) and measure everyday activities with score from 0 to 4.
- Oxford-12 results [ Time Frame: Years : 2 ]Oxford-12 allows to know the feelings of the patient during the last 4 weeks felt from 1 to 5 (satisfaction score).
- Death rate (%) [ Time Frame: Years : 2 ]Analysis of death rate by group.
- Post-operative complications [ Time Frame: Years : 2 ]Analysis of post-operative complications by group.
- Revision surgery for any cause other than infection [ Time Frame: Years : 2 ]Analysis of revision surgery for any cause other than infection.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04251377
|Contact: Bertrand BOYER, MD||(0)477120820 ext +email@example.com|
|Contact: Carine LABRUYERE, CRA||(0)477120469 ext +firstname.lastname@example.org|
|CHU Amiens||Not yet recruiting|
|Sub-Investigator: Benoit BRUNCHWEILER, PhD|
|CHU Bordeaux||Not yet recruiting|
|Sub-Investigator: Thierry FABRE, PhD|
|Sub-Investigator: Frédéric-Antoine DAUCHY, MD|
|CHU Caen||Not yet recruiting|
|Sub-Investigator: Goulven ROCHCONGAR, MD|
|CHU Clermont-Ferrand||Not yet recruiting|
|Sub-Investigator: Stéphane DESCAMPS, MD PhD|
|CHU Dijon||Not yet recruiting|
|Sub-Investigator: Ludovic LABATTUT, MD|
|CHU Lille||Not yet recruiting|
|Sub-Investigator: Henri MIGAUD, MD|
|HCL - Hôpital de la Croix Rousse||Not yet recruiting|
|Principal Investigator: Sébastien LUSTIG, MD PhD|
|Sub-Investigator: Cécile BATAILLER, MD PhD|
|HCL - Hôpital Edouard Herriot||Not yet recruiting|
|Principal Investigator: Frédéric RONGIERAS, MD PhD|
|CHU Marseille||Not yet recruiting|
|Sub-Investigator: Xavier FLECHER, PhD|
|CHU Nancy||Not yet recruiting|
|Sub-Investigator: Didier MAINARD, PhD|
|CHU Nantes||Not yet recruiting|
|Sub-Investigator: Sophie TOUCHAIS, MD|
|Sub-Investigator: Yoann VARENNE, MD|
|CHU Nice||Not yet recruiting|
|Sub-Investigator: Régis DE DOMPSURE, MD|
|Principal Investigator: Bertrand BOYER, MD|
|CHU Toulouse||Not yet recruiting|
|Sub-Investigator: Nicolas REINA, PhD|
|Principal Investigator:||Bertrand BOYER, MD||CHU SAINT-ETIENNE|